News | Implantable Cardioverter Defibrillator (ICD) | November 04, 2015

LivaNova Launches Platinum ICD/CRT-D Family

Released simultaneously in both Europe and Japan, devices will protect patients from avoidable replacement surgeries

LivaNova, Platinum, ICD, CRT-D, launch, Europe and Japan

Image courtesy of LivaNova PLC

November 4, 2015 — LivaNova PLC, formerly Sorin Group, launched Platinum, a new range of implantable cardiac defibrillators (ICDs) and cardiac resynchronization therapy devices (CRT-Ds).

Platinum offers superior longevity thanks to technology that ensures extremely low electrical intrinsic consumption. In standard functioning conditions, the service life is projected to last over 14 years for the single-chamber ICD model, over 13 years for the dual-chamber ICD model and over 10 years for CRT-D devices.

More than 60 percent of patients are under 70 years of age at the time of their first implant, and more than one-third will require at least one replacement due to battery depletion. Replacement procedures are associated with twice as many surgical re-interventions as compared to de-novo procedures due to increased rates of complications, such as infections. The mortality rate in patients with an infection reaches 16.9 percent at one year and 27.5 percent at three years.

The longevity of Platinum aims to limit the number of device replacements, minimizing the risks that are inherent in replacement surgeries. That longevity has been achieved without compromising the size of the device: Platinum’s size ranges from 31cc to 33cc, and the ErgoformM design of the can, with its rounded shape and smooth edges, was designed to facilitate the implant procedure and improve patient comfort.

Platinum devices also feature proven therapeutic functions such as the PARAD+ arrhythmia discrimination algorithm; SafeR, a pacing mode which preserves natural heart conduction; and SonR, a hemodynamic sensor which automatically optimizes CRT settings.

For more information: www.livanova.com

Related Content

A view of the EPD Solutions catheter ablation system image guidance. It displays the catheter within a pre-acquired 3D segmented CT image. The D700 system provides a real-time lesion assessment tool that predicts transmurality and permanency of lesions, pre- and immediately post-ablation.

A view of the EPD Solutions catheter ablation system image guidance. It displays the catheter within a pre-acquired 3D segmented CT image. The D700 system provides a real-time lesion assessment tool that predicts transmurality and permanency of lesions, pre- and immediately post-ablation.

News | EP Lab | June 05, 2018
June 5, 2018 — Philips Healthcare has signed an agreement to acquire EPD Solutions, a provider of image-guidance in c
A recent study shows the Baylis NRG radiofrequency (RF) Transseptal puncture catheter has a lower incidence of embolism in EP cases.
News | EP Lab | May 21, 2018
May 21, 2018 — A recent study published in Heart and Vessels has found that the use of the Baylis Medical NR
Myocarditis is an Under-recognized Etiology of Symptomatic Premature Ventricular Arrhythmia (PVCs). #HRS #HRS2018
News | EP Lab | May 18, 2018
May 18, 2018 — A significant number of patients with symptomatic premature ventricular contractions (PVCs) have under
Novel Antibiotics Can Help Lower EP Device Infection Rates. Pictured here is an ICD. Implantation of pacemakers, ICDs and the related cardiac leads opens patients to infection risk.

Implantation of pacemakers, ICDs and the related cardiac leads opens patients to infection risk.

News | EP Lab | May 17, 2018
May 10, 2018 – A new study is the first to test the clinical effectiveness of incremental peri-operative antibiotics
The Apple Watch Series 2, Samsung Galaxy Gear S3 and the Fitbit Charge 2 were all able to properly diagnose the very rapid heart beats involved in  paroxysmal supraventricular tachycardia (PSVT). #HRS2018

The Apple Watch Series 2, Samsung Galaxy Gear S3 and the Fitbit Charge 2 were all able to properly diagnose the very rapid heart beats involved in  paroxysmal supraventricular tachycardia (PSVT).  

News | EP Lab | May 16, 2018
May 16, 2018 — A new study is the first to validate the accuracy of wrist-worn wearable devices in measuring induced
LivaNova Completes Sale of Cardiac Rhythm Management (CRM - electrophysiology) Business to MicroPort Scientific
News | EP Lab | April 30, 2018
April 30, 2018 — LivaNova announced it completed the sale of its cardiac rhythm management (CRM) business to MicroPor
LivaNova Enters Binding Letter of Intent to Sell Cardiac Rhythm Management Business
News | EP Lab | January 26, 2018
January 26, 2018 — LivaNova PLC and MicroPort Scientific Corp.
Societies Detail Treatment for Patients With Ventricular Arrhythmias
News | EP Lab | October 30, 2017
The American College of Cardiology, along with the American Heart Association and the Heart Rhythm Society, published...
Baylis Medical and Siemens Co-Sponsor Transseptal Access Training Course
News | EP Lab | October 18, 2017
Baylis Medical Co. Inc. and Siemens Healthineers are co-sponsoring a first-of-its kind training program aimed at...
Spectranetics Initiates Class I Recall for Bridge Occlusion Balloon Catheter
News | EP Lab | September 27, 2017
Spectranetics is recalling its Bridge Occlusion Balloon Catheter due to the possibility of a blocked guidewire lumen in...
Overlay Init